Skip to main content

Numaqula Omega-3 Disease Interactions

There are 7 disease interactions with Numaqula Omega-3 (cholecalciferol / lutein / omega-3 polyunsaturated fatty acids / zeaxanthin).

Major

Vitamin D analogs (applies to Numaqula Omega-3) arrhythmia

Major Potential Hazard, High plausibility. Applicable conditions: Arrhythmias

Vitamin D analogs function to increase serum calcium concentrations and can exacerbate arrhythmias, particularly in patients receiving cardiac glycosides. Therapy with vitamin D analogs should be administered cautiously in patients with or predisposed to cardiac arrhythmias. Clinical monitoring of serum electrolyte concentrations and cardiac function is recommended.

References

  1. (2001) "Product Information. Calciferol (ergocalciferol)." Schwarz Pharma
  2. (2001) "Product Information. Rocaltrol (calcitriol)." Roche Laboratories
  3. (2001) "Product Information. Calderol (calcifediol)." Organon
Major

Vitamin D analogs (applies to Numaqula Omega-3) electrolyte imbalance

Major Potential Hazard, High plausibility. Applicable conditions: Phosphate Imbalance

Vitamin D analogs administered in the presence of hyperphosphatemia can result in precipitation of calcium-phosphate deposits within the vascular or renal systems or other soft tissue calcifications. A solubility product (Serum Calcium X Phosphate) should not exceed 70. Serum electrolyte concentrations should be corrected prior to vitamin D analog therapy and monitored during therapy.

References

  1. (2001) "Product Information. Calciferol (ergocalciferol)." Schwarz Pharma
  2. (2001) "Product Information. Rocaltrol (calcitriol)." Roche Laboratories
  3. (2001) "Product Information. Calderol (calcifediol)." Organon
  4. (2001) "Product Information. Zemplar (paricalcitol)." Abbott Pharmaceutical
View all 4 references
Major

Vitamin D analogs (applies to Numaqula Omega-3) hypercalcemia

Major Potential Hazard, Moderate plausibility. Applicable conditions: Malabsorption Syndrome

Vitamin D analogs such as calciferol and ergocalciferol should not be given to patients with hypercalcemia, malabsorption syndrome, or evidence of vitamin D toxicity.

References

  1. (2001) "Product Information. Rocaltrol (calcitriol)." Roche Laboratories
  2. (2001) "Product Information. Zemplar (paricalcitol)." Abbott Pharmaceutical
  3. (2002) "Product Information. Delta D3 (cholecalciferol)." Freeda Vitamins Inc
  4. (2016) "Product Information. Drisdol (ergocalciferol)." sanofi-aventis
View all 4 references
Major

Vitamin D analogs (applies to Numaqula Omega-3) renal dysfunction

Major Potential Hazard, High plausibility.

Ergocalciferol, cholecalciferol, and calcifediol undergo renal biotransformation during metabolic activation. Renal impairment can alter metabolic and therapeutic activity of certain vitamin D analogs. Alternative vitamin D analogs such as dihydrotachysterol (hepatic activation) and calcitriol (active form) may be considered in patients with compromised renal function.

References

  1. (2001) "Product Information. Calciferol (ergocalciferol)." Schwarz Pharma
  2. (2001) "Product Information. Rocaltrol (calcitriol)." Roche Laboratories
  3. (2001) "Product Information. Calderol (calcifediol)." Organon
Moderate

Omega-3 fatty acids (applies to Numaqula Omega-3) arrhythmias

Moderate Potential Hazard, Moderate plausibility.

Cases of recurrent atrial fibrillation (AF) or flutter have been reported with the use of omega-3 fatty acids in patients with a symptomatic paroxysmal AF or persistent AF. This condition is more apparent within the first 2 to 3 months after the initiation of therapy. Therapy with these agents should be administered cautiously in patients with cardiac conduction disorders.

References

  1. (2005) "Product Information. Omacor (omega-3 polyunsaturated fatty acids)." Abbott Pharmaceutical
Moderate

Omega-3 fatty acids (applies to Numaqula Omega-3) liver disease

Moderate Potential Hazard, Moderate plausibility.

Increases in alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) levels have been observed in patients receiving omega-3 fatty acids. Therapy with omega-3 fatty acid preparations should be administered cautiously in patients with hepatic impairment. Serum liver enzyme levels should be monitored periodically.

References

  1. (2005) "Product Information. Omacor (omega-3 polyunsaturated fatty acids)." Abbott Pharmaceutical
  2. (2021) "Product Information. Lovaza (omega-3 polyunsaturated fatty acids)." Woodward Pharma Services, Rev. 02-2021-00
Moderate

Vitamin D analogs (applies to Numaqula Omega-3) hepatobiliary dysfunction

Moderate Potential Hazard, High plausibility. Applicable conditions: Liver Disease, Biliary Obstruction

Vitamin D analogs are fat soluble and oral formulations require bile for adequate intestinal absorption. Hepatic and/or biliary dysfunction decrease the absorption of vitamin D analogs. Metabolites of vitamin D analogs are primarily excreted in bile and feces. Ergocalciferol, cholecalciferol, and dihydrotachysterol undergo hepatic hydroxylation during metabolic activation. Hepatic impairment can alter the metabolic and therapeutic activity of certain vitamin D analogs. Alternative vitamin D analogs such as calcifediol (requires renal activation) and calcitriol (active form) may be considered in patients with compromised hepatic function.

References

  1. (2001) "Product Information. Calciferol (ergocalciferol)." Schwarz Pharma
  2. (2001) "Product Information. Rocaltrol (calcitriol)." Roche Laboratories
  3. (2001) "Product Information. Calderol (calcifediol)." Organon

Numaqula Omega-3 drug interactions

There are 149 drug interactions with Numaqula Omega-3 (cholecalciferol / lutein / omega-3 polyunsaturated fatty acids / zeaxanthin).


Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.